{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:04:58Z","timestamp":1790636698698,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ejps.2020.105460","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T11:28:18Z","timestamp":1594034898000},"page":"105460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Gastrointestinal diseases and their impact on drug solubility: Celiac disease"],"prefix":"10.1016","volume":"152","author":[{"given":"Angela","family":"Effinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6915-6201","authenticated-orcid":false,"given":"Caitriona M","family":"O'Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1826-7363","authenticated-orcid":false,"given":"Nikoletta","family":"Fotaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2020.105460_bib0001","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/je900376r","article-title":"Solubility of budesonide, hydrocortisone, and prednisolone in ethanol\u00a0+\u00a0water mixtures at 298.2K","volume":"55","author":"Ali","year":"2010","journal-title":"J. Chem. Eng. Data"},{"key":"10.1016\/j.ejps.2020.105460_bib0002","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2020.105460_bib0003","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jpba.2007.10.030","article-title":"Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound","volume":"46","author":"Baka","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2020.105460_bib0004","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.2042-7158.1993.tb05627.x","article-title":"Partitioning and thermodynamics of dipyridamole in the n-octanol\/buffer and liposome systems","volume":"45","author":"Betageri","year":"1993","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105460_bib0005","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2174\/1386207319666160502123917","article-title":"Determining partition coefficient (Log P), distribution coefficient (Log D) and ionization constant (pKa) in early drug discovery","volume":"19","author":"Bharate","year":"2016","journal-title":"Comb. Chem. High Throughput Screen"},{"key":"10.1016\/j.ejps.2020.105460_bib0006","article-title":"Solubility enhancement of budesonide and statistical optimization of coating variables for targeted drug delivery","volume":"2014","author":"Bhatt","year":"2014","journal-title":"J. Pharm. (Cairo)"},{"key":"10.1016\/j.ejps.2020.105460_bib0007","series-title":"Physics and Chemistry of Interfaces","first-page":"4","article-title":"Liquid Surfaces","author":"Butt","year":"2004"},{"key":"10.1016\/j.ejps.2020.105460_bib0008","article-title":"Transdermal formulations of fluticasone (US 2016\/0081915)","author":"Corey","year":"2016","journal-title":"Google Patents."},{"key":"10.1016\/j.ejps.2020.105460_bib0009","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1021\/jacs.6b11215","article-title":"Structure-kinetic relationships of passive membrane permeation from multiscale modeling","volume":"139","author":"Dickson","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejps.2020.105460_bib0010","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jphp.12928","article-title":"Impact of gastrointestinal disease states on oral drug absorption - implications for formulation design - a PEARRL review","volume":"71","author":"Effinger","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105460_bib0012","unstructured":"G.D. Searle LLC Division of Pfizer Inc, 2019. CELEBREX- celecoxib capsule prescribing information, New York, NY, US. Available from: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=793[accessed 09.06.2019]."},{"key":"10.1016\/j.ejps.2020.105460_bib0011","article-title":"Gastrointestinal diseases and their impact on drug solubility: Crohn\u2019s disease","author":"Effinger","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105460_bib0013","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1023\/A:1011910801212","article-title":"Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs","volume":"15","author":"Galia","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2020.105460_bib0014","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/gastro\/gov006","article-title":"Development of drugs for celiac disease: review of endpoints for Phase 2 and 3 trials","volume":"3","author":"Gottlieb","year":"2015","journal-title":"Gastroenterol. Rep. (Oxf)"},{"key":"10.1016\/j.ejps.2020.105460_bib0015","series-title":"Compendium of Inflammatory Diseases","first-page":"1","article-title":"Sulfasalazine and Related drugs","author":"Graham","year":"2015"},{"key":"10.1016\/j.ejps.2020.105460_bib0016","series-title":"Exploring QSAR:\u2009 Hydrophobic, Electronic, and Steric Constants","author":"Hansch","year":"1995"},{"key":"10.1016\/j.ejps.2020.105460_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/ci800436c","article-title":"Findings of the challenge to predict aqueous solubility","volume":"49","author":"Hopfinger","year":"2009","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejps.2020.105460_bib0018","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s11095-008-9569-4","article-title":"Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update","volume":"25","author":"Jantratid","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2020.105460_bib0019","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1002\/jps.24470","article-title":"Fasted-state simulated intestinal fluid \"FaSSIF-C\", a cholesterol containing intestinal model medium for in vitro drug delivery development","volume":"104","author":"Khoshakhlagh","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105460_bib0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/cs0630373","article-title":"Altered jejunal surface pH in coeliac disease: its effect on propranolol and folic acid absorption","volume":"63","author":"Kitis","year":"1982","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ejps.2020.105460_bib0021","series-title":"Celiac Disease and Gluten","first-page":"1","article-title":"Chapter 1 Celiac Disease\u2014A Complex Disorder","author":"Koehler","year":"2014"},{"key":"10.1016\/j.ejps.2020.105460_bib0022","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrgastro.2015.131","article-title":"Extraintestinal manifestations of coeliac disease","volume":"12","author":"Leffler","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejps.2020.105460_bib0023","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","article-title":"Classification of orally administered drugs on the world health organization model list of essential medicines according to the biopharmaceutics classification system","volume":"58","author":"Lindenberg","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2020.105460_bib0024","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1021\/ci800058v","article-title":"Solubility challenge: can you predict solubilities of 32 molecules using a database of 100 reliable measurements?","volume":"48","author":"Llinas","year":"2008","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.ejps.2020.105460_bib0025","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/gut.14.3.204","article-title":"The effect of coeliac disease upon bile salts","volume":"14","author":"Low-Beer","year":"1973","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2020.105460_bib0026","first-page":"25","article-title":"The pK(a) distribution of drugs: application to drug discovery","volume":"1","author":"Manallack","year":"2007","journal-title":"Perspect. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105460_bib0027","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejpb.2015.03.009","article-title":"In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: choosing the appropriate test media","volume":"93","author":"Markopoulos","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2020.105460_bib0028","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0378-5173(87)90085-8","article-title":"Kinetics of azathioprine degradation in aqueous solution","volume":"35","author":"Mitra","year":"1987","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105460_bib0029","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/00042737-199910000-00019","article-title":"The histopathology of coeliac disease: time for a standardized report scheme for pathologists","volume":"11","author":"Oberhuber","year":"1999","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejps.2020.105460_bib0030","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0022-3565(24)29580-X","article-title":"Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption","volume":"297","author":"Paulson","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ejps.2020.105460_bib0031","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0378-4347(00)82069-1","article-title":"Specific determination of dipyridamole in serum by high-performance liquid chromatography","volume":"162","author":"Pedersen","year":"1979","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.ejps.2020.105460_bib0032","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijpharm.2015.03.006","article-title":"Inter-subject variability in intestinal drug solubility","volume":"485","author":"Rabbie","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105460_bib0033","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/jps.24603","article-title":"Characterization of human duodenal fluids in fasted and fed state conditions","volume":"105","author":"Riethorst","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105460_bib0034","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1002\/jps.21287","article-title":"Measurement of dissociation constants (pKa values) of organic compounds by multiplexed capillary electrophoresis using aqueous and cosolvent buffers","volume":"97","author":"Shalaeva","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105460_bib0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejpb.2009.05.009","article-title":"Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling","volume":"73","author":"Shono","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2020.105460_bib0036","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1021\/mp100144v","article-title":"Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids","volume":"7","author":"Soderlind","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2020.105460_bib0037","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2146\/ajhp120689","article-title":"Drug absorption in celiac disease","volume":"70","author":"Tran","year":"2013","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejps.2020.105460_bib0038","series-title":"Celiac Disease: Methods and Protocols","first-page":"3","article-title":"Celiac disease: background and historical context","author":"Turner","year":"2015"},{"key":"10.1016\/j.ejps.2020.105460_bib0039","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11095-010-0223-6","article-title":"Biorelevant media to simulate fluids in the ascending colon of humans and their usefulness in predicting intracolonic drug solubility","volume":"27","author":"Vertzoni","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2020.105460_bib0040","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejpb.2005.03.002","article-title":"Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds","volume":"60","author":"Vertzoni","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2020.105460_bib0041","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0016-5085(85)80145-1","article-title":"Increased biliary lipid secretion in celiac disease","volume":"88","author":"Vuoristo","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2020.105460_bib0042","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ejpb.2014.05.020","article-title":"Micelle dynamic simulation and physicochemical characterization of biorelevant media to reflect gastrointestinal environment in fasted and fed states","volume":"88","author":"Xie","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2020.105460_bib0043","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1021\/mp100124f","article-title":"A modified physiological BCS for prediction of intestinal absorption in drug discovery","volume":"7","author":"Zaki","year":"2010","journal-title":"Mol. Pharm."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720302499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720302499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:55:46Z","timestamp":1760529346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098720302499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":43,"alternative-id":["S0928098720302499"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105460","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastrointestinal diseases and their impact on drug solubility: Celiac disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105460"}}